Ipamorelin vs Tesamorelin: a research comparison

Research use only. This content is for laboratory research; not for human or veterinary use, diagnosis, or treatment.

Producto para uso experimental en laboratorio. No es medicamento ni producto de consumo humano.

Ipamorelin and tesamorelin are often grouped within growth-hormone (GH) axis research, but they act on different receptors. This comparison summarizes the mechanistic difference documented in the literature and — most relevant to a lab — how to evaluate and contrast the quality of each compound when sourcing it for research.

What each compound is

Ipamorelin (IP10) is a pentapeptide described as the first selective GH secretagogue: in the original characterization by Raun and colleagues it released GH without significantly raising ACTH or cortisol ^[1]. Tesamorelin (TSM10) is a stabilized 44-amino-acid analogue of GHRH (GH-releasing hormone), studied in human clinical trials ^[2].

• Ipamorelin (IP10): pentapeptide, selective agonist of the GH-secretagogue receptor (GHS-R / ghrelin). Preclinical selectivity characterization ^[1].
• Tesamorelin (TSM10): 44-amino-acid GHRH analogue; backed by published clinical-trial data ^[2].

The key mechanistic difference: two receptors

Both compounds relate to endogenous GH secretion, but through different routes. Ipamorelin acts on the GH-secretagogue receptor (the ghrelin receptor, GHS-R). Tesamorelin acts on the GHRH receptor. That receptor difference is what separates the two approaches at the molecular-design level.

What the published evidence shows

The maturity of the evidence differs. Tesamorelin has human clinical-trial data — the study by Falutz and colleagues in the New England Journal of Medicine is the heaviest published reference ^[2]. Ipamorelin rests mainly on its preclinical selectivity characterization ^[1], with more limited human data. Both references are cited as scientific context for the compounds; they are not a usage guide or an administration recommendation.

How to compare quality when sourcing either one

For a lab, the decision is settled by documentation, not marketing. The criteria are identical for both compounds:

1. Lot-specific certificate of analysis (COA) with HPLC (reverse-phase) purity and mass-spectrometry (MS) identity confirmation.
2. Traceability: a lot number and analysis date that map to the vial you received.
3. Endotoxin (LAL) testing where the in-vitro protocol requires it.
4. Documented storage conditions and stability data for the lyophilized material.

How to choose between them for your protocol

If your research targets the GHRH axis backed by published clinical data, tesamorelin is the compound with the larger volume of human evidence. If the interest centers on a selective secretagogue acting through the ghrelin (GHS-R) route, ipamorelin is the compound characterized for that axis. In either case, prioritize the lot with a verifiable COA and documented purity above any other consideration.